Yahoo
NasdaqGS - Nasdaq Real Time Price USD

10x Genomics, Inc. (TXG)

70.11 -11.44 (-14.03%)
At close: October 30 at 4:00:00 PM EDT
69.80 -0.31 (-0.44%)
After hours: October 30 at 7:23:16 PM EDT
Trade TXG on Coinbase

Key Executives

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name Title Pay Exercised Year Born
Dr. Serge Saxonov Ph.D.
Co-Founder, CEO & Director 1.31M 466k 1977
Dr. Benjamin J. Hindson Ph.D.
Co-Founder, President, Chief Scientific Officer & Director 811.6k -- 1975
Mr. Adam S. Taich
CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer 792.04k -- 1975
Mr. Jim Goodrich
Chief of Global Operations -- -- --
Mr. Michael Schnall-Levin Ph.D.
Founding Scientist & CTO -- -- --
Ms. Cassie Corneau
Manager of Investor Relations & Strategic Finance -- -- --
Dr. Randy Wu
General Counsel and Secretary -- -- --
Ms. Mennah Moustafa
Chief Commercial Officer -- -- --
Mr. Jens Durruthy
Associate Director of Product Management -- -- --

10x Genomics, Inc.

6230 Stoneridge Mall Road
Pleasanton, CA 94588-3260
United States
925 401 7300 https://www.10xgenomics.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
1,178

Description

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Corporate Governance

10x Genomics, Inc.’s ISS Governance QualityScore as of October 1, 2026 is 8. The pillar scores are Audit: 3; Board: 5; Shareholder Rights: 10; Compensation: 6.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 5, 2026 at 8:00 PM UTC

10x Genomics, Inc. Earnings Date

Recent Events

August 7, 2026 at 12:00 AM UTC

10-Q: Periodic Financial Reports

August 6, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 8, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 8, 2026 at 12:00 AM UTC

10-Q: Periodic Financial Reports

May 7, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 24, 2026 at 12:00 AM UTC

DEFA14A: Proxy Statements

February 13, 2026 at 12:00 AM UTC

10-K: Periodic Financial Reports

February 12, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 12, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 14, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: